How to Get Trulicity (Dulaglutide) in Georgia

Trulicity Is Available by Prescription in Georgia

Georgia allows licensed prescribers to write Trulicity (dulaglutide) prescriptions through both in-person visits and telehealth consultations. Dulaglutide is a once-weekly GLP-1 receptor agonist approved by the FDA for glycemic control in adults with type 2 diabetes. The drug mimics the incretin hormone GLP-1, stimulating insulin secretion in a glucose-dependent manner and suppressing glucagon release.

Georgia does not impose any state-specific restrictions on GLP-1 prescribing beyond standard DEA and medical board licensure requirements. Any physician (MD or DO), nurse practitioner, or physician assistant holding an active Georgia license with prescriptive authority can prescribe Trulicity. NPs in Georgia practice under a collaborative agreement with a physician per O.C.G.A. § 43-34-25, which does not restrict GLP-1 prescribing categories.

The typical starting dose is 0.75 mg once weekly, administered subcutaneously in the abdomen, thigh, or upper arm. After at least four weeks, clinicians may increase the dose to 1.5 mg weekly. The maximum approved dose is 4.5 mg once weekly, an option for patients requiring additional A1c reduction.

Telehealth Is a Legal and Practical Route in Georgia

Georgia fully permits telehealth prescribing for non-controlled substances like dulaglutide, making remote consultations one of the fastest pathways to a Trulicity prescription. A Georgia-licensed provider can evaluate your medical history, review lab results, and send a prescription to your preferred pharmacy after a synchronous video or audio visit.

Several telehealth platforms now serve Georgia residents seeking GLP-1 therapy. The consultation typically includes a review of your hemoglobin A1c, fasting glucose, renal function (eGFR), and a personal or family history of medullary thyroid carcinoma, which is a contraindication per the Trulicity label. Many platforms can schedule an appointment within 24 to 72 hours.

Georgia's telehealth parity law (SB 167, enacted 2019) requires commercial insurers to reimburse telehealth visits at the same rate as in-person encounters. This means the cost of your virtual consultation should be covered the same as an office visit under most commercial plans. Patients on Georgia Medicaid, however, should confirm coverage for the visit itself, as the drug may not be covered (see the Medicaid section below).

Labs You Need Before Starting Trulicity in Georgia

Before any Georgia provider prescribes dulaglutide, they will need baseline labs confirming a type 2 diabetes diagnosis and ruling out contraindications. These results can come from any CLIA-certified lab in Georgia or from recent records transferred to a telehealth provider.

Required baseline labs typically include:

• Hemoglobin A1c: confirms diabetes diagnosis (A1c ≥ 6.5%) and establishes a treatment baseline. The American Diabetes Association Standards of Care 2024 recommend A1c testing at least twice yearly for patients on stable therapy.
• Fasting blood glucose or random glucose: supports the A1c finding.
• Comprehensive metabolic panel (CMP): evaluates kidney function (BUN, creatinine, eGFR) and liver enzymes. Dulaglutide dose adjustments are not required for mild-to-moderate renal impairment, but the FDA label recommends monitoring renal function in patients who report severe gastrointestinal side effects.
• Lipase or amylase (in some practices): screens for baseline pancreatic enzyme levels. GLP-1 agonists carry a precaution regarding pancreatitis, though the REWIND trial (N=9,901) reported acute pancreatitis in 0.3% of dulaglutide patients vs. 0.2% of placebo patients over a median 5.4-year follow-up [1].
• Thyroid panel: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a contraindication. A TSH and calcitonin level may be ordered at provider discretion.

Most commercial labs (Quest, Labcorp, and hospital-based labs) in Georgia can process these within one to three business days. Telehealth providers often accept labs drawn within the prior 90 days.

Georgia Medicaid Does Not Cover Trulicity for Type 2 Diabetes

This is a critical detail for the roughly 2.2 million Georgians enrolled in Medicaid or PeachCare for Kids. Georgia Medicaid's preferred drug list does not include Trulicity (dulaglutide) as a covered agent for type 2 diabetes. Patients on Georgia Medicaid seeking GLP-1 therapy may need to work with their prescriber to explore alternatives that are on the state's formulary, such as older GLP-1 agents or other diabetes drug classes.

For patients with commercial insurance, Trulicity coverage is common but almost always subject to prior authorization. Insurers typically require documentation showing that the patient has an A1c above 7.0% despite adherence to metformin (or has a documented metformin intolerance). Step therapy requirements vary by plan. Some plans require failure of two oral agents before approving an injectable GLP-1 agonist.

Eli Lilly offers the Trulicity Savings Card, which can reduce out-of-pocket costs to as little as $25 per month for commercially insured patients. This program does not apply to government-funded insurance, including Medicaid, Medicare, or Tricare.

The list price for Trulicity without insurance ranges from approximately $950 to $1,100 for a 30-day (four-pen) supply, depending on the dose and pharmacy. GoodRx and similar discount programs may reduce this to $750 to $900 at major Georgia chain pharmacies.

The Prior Authorization Process in Georgia

Prior authorization is the single biggest source of delay between your prescription and your first injection. Here is what happens step by step.

Step 1: Prescriber submits a PA request. Your doctor or NP sends clinical documentation to your insurer. This includes your diagnosis code (E11.x for type 2 diabetes), your most recent A1c value, a list of previously tried medications, and a statement of medical necessity. A 2021 AMA survey found that physicians spend an average of 13 hours per week on prior authorization tasks across all drugs.

Step 2: Insurer reviews. Georgia law (O.C.G.A. § 33-24-59.15) requires health insurers to respond to non-urgent prior authorization requests within 5 business days. Urgent requests must receive a response within 24 hours.

Step 3: Approval, denial, or request for additional information. If approved, the authorization is typically valid for 6 to 12 months. If denied, your prescriber can file a peer-to-peer appeal. Denial rates for GLP-1 agonists have increased in recent years as utilization has surged, but most denials for Trulicity in type 2 diabetes patients with documented metformin failure can be overturned on appeal.

Step 4: Prescription released to pharmacy. Once authorized, the prescription can be filled at any licensed Georgia pharmacy or specialty mail-order pharmacy. Most patients receive their Trulicity pens within 1 to 5 business days after PA approval.

Total timeline from initial appointment to first injection: typically 7 to 21 days, depending on whether prior authorization is required and how quickly labs are completed.

503A Compounding Pharmacies in Georgia

Georgia licenses 503A compounding pharmacies under the Georgia Board of Pharmacy. These pharmacies can prepare patient-specific compounded formulations of dulaglutide when a valid prescription exists. A 503A pharmacy compounds medications based on individual prescriptions, unlike 503B outsourcing facilities that produce larger batches without patient-specific prescriptions.

Several 503A pharmacies in the Atlanta metro area and across Georgia offer compounded GLP-1 formulations. Compounded dulaglutide may cost less than brand-name Trulicity, though pricing varies widely by pharmacy. Patients should confirm that the compounding pharmacy holds a current Georgia Board of Pharmacy license and follows USP 797 sterile compounding standards.

It is worth noting that compounded drugs are not FDA-approved and do not undergo the same regulatory review as branded products. The FDA's guidance on compounding clarifies that 503A pharmacies must compound drugs in response to a valid prescription and cannot produce copies of commercially available drugs unless there is a documented shortage. Patients should discuss the risks and benefits of compounded vs. branded Trulicity with their prescriber.

Cardiovascular Benefits Supported by the REWIND Trial

Dulaglutide is not only a glycemic control agent. The REWIND trial (N=9,901), published in The Lancet in 2019, demonstrated that dulaglutide 1.5 mg once weekly reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 12% compared to placebo (HR 0.88 to 95% CI 0.79 to 0.99; P=0.026) over a median follow-up of 5.4 years [1].

What made REWIND unusual among GLP-1 cardiovascular outcomes trials was its population. Only 31% of enrolled participants had established cardiovascular disease at baseline. The majority had cardiovascular risk factors but no prior events. This suggests a primary prevention benefit, a finding that the 2024 ADA Standards of Care now reflects in its recommendation to consider GLP-1 agonists for patients with type 2 diabetes and multiple cardiovascular risk factors, regardless of A1c level [2].

Mean A1c reduction in REWIND was 0.61 percentage points greater with dulaglutide than placebo at 12 months. Mean body weight decreased by approximately 1.5 kg more in the dulaglutide group. These effects were sustained through the 5.4-year follow-up period.

The 2023 AHA/ACC/HFSA Guideline for the Management of Heart Failure also references GLP-1 receptor agonists as a consideration in patients with type 2 diabetes and heart failure with preserved ejection fraction, based on emerging data from multiple trial programs [3].

Transferring a Trulicity Prescription to Georgia

Patients moving to Georgia from another state can transfer an active Trulicity prescription to a Georgia pharmacy. The process is straightforward.

Your current out-of-state pharmacy can transfer the prescription directly to a Georgia pharmacy via phone or electronic transfer. Georgia Board of Pharmacy rules permit one transfer of a non-controlled prescription between pharmacies. If the prescription has refills remaining, the receiving Georgia pharmacy will honor them.

Alternatively, your new Georgia-based provider (in-person or telehealth) can write a fresh prescription after reviewing your medical records and confirming your current dose. This is often the simpler path, especially if your insurance plan changes with a move. A new prescription also resets the prior authorization clock, which may be necessary if your new insurer has different formulary requirements.

Patients transferring from states where they used mail-order specialty pharmacies should confirm that the mail-order pharmacy is licensed to ship to Georgia addresses. Most national specialty pharmacies (CVS Specialty, Accredo, Express Scripts) hold Georgia licenses and can continue shipping without interruption.

What to Expect After Starting Trulicity

The most common side effects of dulaglutide are gastrointestinal: nausea (12.4%), diarrhea (8.9%), vomiting (6.0%), and abdominal pain (6.5%), based on pooled data from the AWARD clinical trial program [4]. These effects are typically dose-dependent and tend to diminish after the first 2 to 4 weeks of treatment.

Your Georgia provider should schedule a follow-up A1c check 3 months after initiation. The ADA recommends an A1c target of <7.0% for most adults, though individualized targets ranging from <6.5% to <8.0% may be appropriate depending on age, comorbidities, and hypoglycemia risk [2]. If A1c remains above target at the 0.75 mg dose, your provider may titrate to 1.5 mg, then 3.0 mg, and up to 4.5 mg at four-week intervals.

Dulaglutide does not cause hypoglycemia when used alone. Risk increases only when combined with insulin or sulfonylureas. Your prescriber should adjust doses of those medications when adding Trulicity to the regimen.